GREY:IPHAF - Post by User
Post by
narcissiston Jan 10, 2012 3:26pm
411 Views
Post# 19387688
Reduced incidence of NODAT?
Reduced incidence of NODAT? If I am reading the reports rightly, ISA's voclosporin's potential as a possible replacement for tacrolimus as the drug of choice in transplantaion hinges on the confirmation of the hinted - but not formally confirmed - superiority of voclosporin in the reduction of ew onset diabetes after transplantataion (NODAT). The PROMISE study hinted at this superiority in the study's results with NODAT results of 1.6% (low dose), 5.7% (mid dose). and 17.7% (high dose). The tacrolimus arm of the study demonstrated a 16.6% NODAT. What then will the typical or optiimum voclosporin dose eventually be? I find the technical descriptions rather vague around this point so I presume that further studies will nail this number down. If optimum doseage is indeed turns out to be in the low to mid-range, we clearly will have a winner here. Who would not prefer using a drug that is from three to ten times less likly to cause diabetes - as these results suggest? If however voclosporin requires dosages in the high range there will be no real advantage - at least in the NODAT area. Everything hinges on this answer - as far as I can ascertain.